Healthcare Services

An Important Factor Driving the Encephalomyelitis Market Is the Impact Of Growing Autoimmune Diseases On Market Growth

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Encephalomyelitis Market During 2026–2030?

The encephalomyelitis market has experienced significant growth in recent years. It is anticipated to increase from $22.58 billion in 2025 to $24.08 billion in 2026, at a compound annual growth rate (CAGR) of 6.6%. This historical expansion can be attributed to several factors including the prevalence of neurological diseases, improved recognition of autoimmune disorders, greater access to diagnostic imaging, the rise in specialist neurology services, and the development of hospital neurology departments.

The encephalomyelitis market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $30.84 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.4%. This forecasted growth is primarily due to factors such as advanced immunotherapies, the implementation of early diagnosis programs, an increasing need for neurological rehabilitation, ongoing research into rare neurological diseases, and the overall growth of healthcare infrastructure. Key trends anticipated during this period encompass a heightened awareness of neuroinflammatory disorders, a rise in the diagnosis of autoimmune neurological conditions, a growing requirement for long-term neurological care, the broadening of immunomodulatory treatment strategies, and a strong emphasis on early neurological intervention.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21182&type=smp

What Drivers Are Expected To Influence The Encephalomyelitis Market During The Forecast Period?

The increasing incidence of autoimmune conditions is anticipated to drive the expansion of the encephalomyelitis market in the future. Autoimmune diseases are characterized by the body’s immune system mistakenly attacking its own healthy cells and tissues. The surge in these diseases stems from various factors, including genetic predispositions, environmental factors, infections, and evolving lifestyle aspects such as dietary habits and chemical exposure. Encephalomyelitis treatments offer crucial support to individuals suffering from autoimmune diseases by mitigating inflammation, regulating immune system irregularities, easing neurological manifestations, and halting disease progression, thereby enhancing their overall quality of life and functional health. For instance, in February 2024, data from Arthritis Australia, an Australia-based non-profit organization, indicated that in 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Consequently, the rising prevalence of autoimmune diseases is fueling the growth of the encephalomyelitis market.

How Are The Various Segments Of The Encephalomyelitis Market Categorized?

The encephalomyelitis market covered in this report is segmented –

1) By Type: Equine Encephalomyelitis, Associated Encephalomyelitis, Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG), Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis, Other Types

2) By Treatment: Surgery, Plasmapheresis, Drug Treatment, Other Treatments

3) By End-users: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Equine Encephalomyelitis: Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis

2) By Associated Encephalomyelitis: Post-Infectious Encephalomyelitis, Paraneoplastic Encephalomyelitis, Vaccine-Associated Encephalomyelitis

3) By Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG): MOG Antibody-Positive Encephalomyelitis, MOG Antibody-Associated Neuromyelitis Optica Spectrum Disorder

4) By Encephalomyelitis Disseminata: Multiple Sclerosis-Related Encephalomyelitis, Relapsing-Remitting Encephalomyelitis Disseminata, Progressive Encephalomyelitis Disseminata

5) By Acute Disseminated Encephalomyelitis: Post-Viral Acute Disseminated Encephalomyelitis, Post-Vaccination Acute Disseminated Encephalomyelitis

6) By AIDS-Related Encephalomyelitis: HIV-Associated Encephalomyelitis, Opportunistic Infection-Related Encephalomyelitis, Other AIDS-Related Encephalomyelitis

7) By Other Types: Idiopathic Encephalomyelitis, Autoimmune Encephalomyelitis, Rare Genetic Encephalomyelitis Variants

Which Upcoming Trends Are Expected To Influence The Encephalomyelitis Market?

Companies active in the encephalomyelitis market are prioritizing the development of advanced monoclonal antibodies to boost treatment efficacy and formulate targeted therapies for managing encephalomyelitis. A monoclonal antibody is a synthetic protein engineered to attach to specific antigens, thereby aiding the immune system’s response against various diseases. For instance, in March 2023, Chugai Pharmaceutical Co. Ltd, a Japan-based pharmaceutical company, announced that its humanized anti-IL-6 receptor monoclonal antibody, Enspryng, had received forerunner designation from the Ministry of Health, Labor and Welfare (MHLW) for its projected use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). This designation acknowledges Enspryng’s potential as an innovative treatment, which helps accelerate its development and regulatory review to fulfill the unmet medical needs of patients with these neurological conditions.

Which Major Firms Influence Developments In The Encephalomyelitis Market?

Major companies operating in the encephalomyelitis market are Merck & Co. Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., HiFiBiO Therapeutics, Zoetis Services LLC, Chugai Pharmaceutical Co. Ltd., IDEXX, Abcam Limited., EUROIMMUN Medizinische Labordiagnostika AG, Eurogentec S.A., Boehringer Ingelheim International GmbH, Creative Diagnostics, Atlas Antibodies, AnaSpec, VMRD Inc., Antibodies Incorporated, Fresenius Kabi, Hemispherx Biopharma Inc., BioStoneah, YouSeq Ltd.

Read the full encephalomyelitis market report here:

https://www.thebusinessresearchcompany.com/report/encephalomyelitis-global-market-report

Which Region Is Forecast To Lead The Encephalomyelitis Market In Terms Of Market Size?

North America was the largest region in the encephalomyelitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the encephalomyelitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Encephalomyelitis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21182&type=smp

Browse Through More Reports Similar to the Global Encephalomyelitis Market 2026, By The Business Research Company

Encephalitis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/encephalitis-treatment-global-market-report

Hepatic Encephalopathy Global Market Report

https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report

Progressive Multifocal Leukoencephalopathy Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795